Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.
about
Combating Tuberculosis Infection: A Forbidding ChallengeIdentification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrBBiochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug targetNew anti-tuberculosis drugs and regimens: 2015 updateRepurposing clinically approved cephalosporins for tuberculosis therapyTuberculosis therapy for 2016 and beyond.Insights into the pharmacokinetic properties of antitubercular drugs.SQ109, a new drug lead for Chagas disease.In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis.Multitarget drug discovery for tuberculosis and other infectious diseases.The mycobacterial cell envelope-lipidsInvestigational antimicrobial agents of 2013.The cell envelope glycoconjugates of Mycobacterium tuberculosisNovel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.RND transporters protect Corynebacterium glutamicum from antibiotics by assembling the outer membrane.A Nano-MgO and Ionic Liquid-Catalyzed 'Green' Synthesis Protocol for the Development of Adamantyl-Imidazolo-Thiadiazoles as Anti-Tuberculosis Agents Targeting Sterol 14α-Demethylase (CYP51).New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.Screening the Pathogen Box for Identification of Candida albicans Biofilm InhibitorsAntiinfectives targeting enzymes and the proton motive force.Targeting the trehalose utilization pathways of Mycobacterium tuberculosisAdvances in Drug Discovery and Development for Pediatric Tuberculosis.Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.Indoleamides are active against drug-resistant Mycobacterium tuberculosisSynergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.Discovery of a Structurally Unique Small Molecule that Inhibits Protein SynthesisProspects for new antibiotics: a molecule-centered perspective.Resistance in tuberculosis: what do we know and where can we go?Trends in discovery of new drugs for tuberculosis therapy.The future for early-stage tuberculosis drug discoveryNovel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model.The anti-tuberculosis agents under development and the challenges ahead.Synthetic investigational new drugs for the treatment of tuberculosis.The paradigm shift to end tuberculosis. Are we ready to assume the changes?Emerging drugs and alternative possibilities in the treatment of tuberculosis.Inhibition of Leishmania mexicana Growth by the Tuberculosis Drug SQ109Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Drug Resistance Mechanisms in Mycobacterium tuberculosis.Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).
P2860
Q26750683-1236022C-C182-4F69-81EC-63746D29927FQ28484670-27DA892F-DE81-4EB2-BEF2-E28D68D96EA2Q28545065-EDBD71C8-2FC1-4EAA-87F3-C5B1212D3A27Q28596775-F09713A1-6C82-433D-8E59-550D578D7889Q28828720-88AC8494-71C4-409B-9045-CA4744E1FC3AQ30248788-E38761ED-33E7-47EA-8A11-4801C5D4CBE7Q30251497-4E20CD6B-0912-4F44-BF71-A7E4ACD68F1AQ30626912-4D5F7880-F706-4B46-B21D-DE385B37D8E8Q33798527-D6C29C1A-C589-4EE5-98E7-CA4758DA8B11Q33854785-63FB41D5-6354-40A6-8EE3-F21D7D30073DQ34355375-4749580A-276A-411F-89D5-1E7B6D33C211Q34375204-6AF317CC-C1D3-47E6-9D8D-92C99183B269Q34423962-90FA56B1-A6CA-4A6C-B4B1-0EDFD42E9013Q34596427-D76B1F9E-50CA-4E5D-A767-0D1D0F62E02BQ34870110-329F86E4-BCB4-4F02-8A81-8034CD3FA0F8Q35808907-2DE58EE7-6412-424C-8855-583D7E5268D3Q36057012-8D9135A6-4F33-45C0-BCDE-090E24D47E28Q36094215-ABD25F20-B555-46EE-94A0-7665A016CEF8Q36177985-767B418B-618B-423F-8021-AA2CAA3C66ACQ36419761-02A0952C-BA1A-453C-9E37-A4A3EE672D99Q36629840-BF91F52D-24FF-4A22-9E0D-48A5265E2AADQ37134041-CD0BFBA2-C062-437B-BF95-65B7CE65A625Q37203793-FF5B8544-21BE-4366-9F4B-639D2A380089Q37507802-A307102B-523F-40A9-811C-306CA4AD38B2Q37541307-6854EFD6-F92E-4226-AB63-92705C7F71D2Q37720810-BBAF0BD1-F5DD-4E96-BE51-913E078447B6Q37724398-F856110E-5E9C-4BA4-97C6-F6B1A00D948EQ38113689-7B67F7BF-AD59-4F7A-A88B-FA5D3B3EC46CQ38124261-03BBB527-D48F-43DC-BA75-487C1EDBBC23Q38237221-6610C1C2-9723-4330-9DFA-06ED982982FCQ38358621-A7E9E2E8-A30C-42C0-9907-86E66520670EQ38441471-9876E0FE-CD61-4789-BC77-135727E52810Q38617197-431D5EDA-F003-4959-BDE7-06CECCDDCE1EQ38635790-03D94CB8-BC6C-4214-BDC2-0709D881CF13Q38676708-874274B1-4AD3-4E42-A95F-0B0F166D351FQ38724073-AE92B1F0-2969-4478-A697-2DCD5BE78CF6Q38755807-1F4355D6-EDE3-4A44-9D92-8BF8B332957BQ38782638-0FACBBCE-2BDE-44A1-8A52-C2136989E4C1Q38792870-38FD5227-3C72-420F-B7D4-ECA4933D7821Q38845466-3C6ADC53-4CAF-4E55-BE21-3BB241C92CBD
P2860
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Discovery and development of S ...... h a novel mechanism of action.
@ast
Discovery and development of S ...... h a novel mechanism of action.
@en
type
label
Discovery and development of S ...... h a novel mechanism of action.
@ast
Discovery and development of S ...... h a novel mechanism of action.
@en
prefLabel
Discovery and development of S ...... h a novel mechanism of action.
@ast
Discovery and development of S ...... h a novel mechanism of action.
@en
P2093
P2860
P356
P1433
P1476
Discovery and development of S ...... h a novel mechanism of action.
@en
P2093
Carol A Nacy
Katherine A Sacksteder
Koen Andries
Marina Protopopova
P2860
P304
P356
10.2217/FMB.12.56
P577
2012-07-01T00:00:00Z